INTRODUCTION
============

Renal cell carcinoma (RCC) is the most common malignancy of the kidney and a cancer of increasing incidence \[[@B1]\]. In Korea, RCC accounted for 1.85% of the total cancer occurrence in 2012, and the incidence rate was 8.2 per 100,000 people \[[@B2]\]. The incidence of this cancer is relatively low among genitourinary malignancy, leading to the management of a lower volume of RCC cases in most hospitals. Therefore, it is difficult to make generalizations based on studies of RCC performed by single center due to the lower number of cases and the possibility of selection bias. Therefore, it is necessary to establish a well-qualified multi-institutional database (DB) system comprising a large cohort to conduct clinical RCC researches due to the lower incidence of this neoplasm. And this database should include more variable data than the cancer statistics of National Cancer Center or Health Insurance Review & Assessment service.

Some international groups have performed RCC studies based on multi-institutional RCC DBs. Examples include the renal mass study of CROES (Clinical Research Office of the Endourological Society) \[[@B3][@B4]\], CORONA (Collaborative Research On Renal Neoplasms Association) Project \[[@B5] [@B6][@B7][@B8][@B9]\], SATURN (Surveillance and Treatment Update Renal Neoplasms) Projects \[[@B8][@B9]\] and Japanese multicenter studies \[[@B10][@B11]\], which have reported high-quality research results. Some multi-institutional retrospective studies on RCC have also been conducted in Korea \[[@B12][@B13][@B14]\], but there have been no large DB systems to collect data on Korean RCC. Here, we report the establishment of the 1st Web-based RCC DB system in Korea (KOrean Renal Cell Carcinoma, KORCC) and summarize the basic characteristics of Korean patients with RCC who underwent surgical management.

MATERIALS AND METHODS
=====================

The new Web-based DB system was established to collect basic demographic and clinicopathological characteristics of a large cohort of patients with RCC in Korea. This project was approved by local ethics committee at Seoul National University Bundang Hospital (IRB number: B1202/145-102). The data included basic demographic (such as age, gender, height, and weight) and clinicopathological characteristics (such as clinical stage, perioperative parameters, pathological stage, Fuhrman nuclear grade and survival data) ([Tables 1](#T1){ref-type="table"}, [2](#T2){ref-type="table"}, [3](#T3){ref-type="table"}, [4](#T4){ref-type="table"}, [5](#T5){ref-type="table"}). AJCC cancer staging manual was used for TNM staging \[[@B15]\]. Private information (such as resident registration number and hospital ID number) was excluded to protect the patients\' personal information.

Data from a total of 6,849 patients were collected from 8 tertiary care hospitals that agreed to participate in organizing KORCC study group as of 1 July 2015. These hospitals were Chonnam National University Hwasun Hospital (308 cases), Chungbuk National University Hospital (178 cases), Korea University Anam Hospital (105 cases), Kyungpook University Medical Center (890 cases), National Cancer Center (618 cases), Seoul St. Mary\'s Hospital (883 cases), Seoul National University Bundang Hospital (1,440 cases) and Seoul National University Hospital (2,427 cases). Data were collected for the management of renal masses of all tumor stages (pT1-4, N0-2, M0-1) at the Department of Urology at each hospital from 1990 to present (time frame varies among hospitals due to differences in their own DB collections). Hospitals have contributed to the database by adding all consecutive patients until now.

We analyzed the data of patients who underwent surgical treatments. They were compared with those of previous international studies to characterize Korean RCC. Some data were excluded from the analysis due to insufficient or missing variables.

RESULTS
=======

We established the 1st Web-based DB of KORCC, a database comprising renal mass management cases from multiple centers in Korea ([www.mebica.net](http://www.mebica.net)). A total of 6,849 patients were collected nationwide from 8 tertiary care hospitals in Korea.

We analyzed data of 5,281 patients with surgical management (mean follow-up \[FU\], 32 months) ([Tables 1](#T1){ref-type="table"}, [2](#T2){ref-type="table"}, [3](#T3){ref-type="table"}, [4](#T4){ref-type="table"}, [5](#T5){ref-type="table"}). The patients\' mean age was 55.7±12.7 years, and 71.2% of the patients were male ([Fig. 1](#F1){ref-type="fig"}). Hypertension, diabetes mellitus and chronic kidney disease (defined as grade 3 or more) were identified in 38.5%, 14.9%, and 19.4% of the patients, respectively. The most common symptom was incidentally detected renal mass (4,048 cases, 76.9%), and the 2nd most common was gross hematuria, which accounted for 10.4%.

Preoperative characteristics-such as clinical stage, tumor size, laterality, and location-were described in [Table 2](#T2){ref-type="table"}. Clinical T1a was the most common (54.3%) stage, and the mean tumor size was 4.8±4.2 cm.

Radical nephrectomy accounted for 62.7% of the total cases, and an open approach was used in 50.7% and 52.2% of radical and partial nephrectomies, respectively ([Table 3](#T3){ref-type="table"}). Warm ischemia was the most common type of ischemia (83.0%) and mean ischemic time was 25.2±11.3 minutes.

Intraoperative and postoperative transfusions were done in 7.2% and 3.6% of the patients, respectively ([Table 4](#T4){ref-type="table"}). Intraoperative and postoperative complications occurred in 6.9% and 10.3% of the patients, respectively. A total of 2.9% of severe postoperative complications were of Clavien-Dindo grade ≥3 \[[@B16]\].

Pathological characteristics are shown in [Table 5](#T5){ref-type="table"}. T1a accounted for 55.2% of the total cases. The most common nuclear grade was Fuhrman grade 2 (51.8%) and the most common histological type was clear cell (85.2%). Positive surgical margins were identified in 4.0% of the patients undergoing partial nephrectomy.

The 5-year overall, cancer-specific and recurrence-free survival rates were 88.1%, 92.2%, and 88.0%, respectively ([Table 6](#T6){ref-type="table"}). Kaplan-Meier survival curves according to stage, nuclear grade and histologic type are shown in [Figs. 1](#F1){ref-type="fig"}, [2](#F2){ref-type="fig"}.

DISCUSSION
==========

We report the 1st establishment of a Web-based DB system to collect clinicopathological characteristics of RCC in Korea. This project was initiated with the aid of 5 participating centers in 2011. The KORCC Web-based DB system was launched in 2013, finally leading to the participation of 8 centers nationwide in 2014. There are already some publications through the use of this DB \[[@B14][@B17][@B18]\]. It is necessary to collect data from a large cohort of RCC patients to provide better analysis of RCC data in Korea. Data from approximately 7,000 RCC cases were collected, and this project remains ongoing to collect more cases. We believe that this DB can represent Korean RCC due to its large cohort size and nationwide distribution.

Several factors were of concern in the establishment of this system. First, we aimed to collect data that was representative of Korean RCC. Therefore, we invited 8 nationwide tertiary care centers to participate in this project, and they all agreed to join. This led to the creation of a DB that represents RCC characteristics of Korean patients. Second, because this system is Web-based, there is possibility that patients\' data could be leaked due to security problems. Therefore, we chose an experienced company that has built many Web-based clinical trial DB systems (Mebixon Co., Seoul, Korea). Personal information-such as resident registration number and hospital identification number-was not included in our DB system. This led to the establishment of a secure Web-based DB system of RCC in Korea.

For the good quality of this database, we limited the number of hospital as above. In the future, if the database works well, we will invite other hospitals to participate in KORCC and provide chances to investigate with this database.

There have been many multicenter based studies on RCC, and CROES was the 1st group to establish an international electronic data management system \[[@B3]\]. The global renal mass study driven by CROES was started in 2008 to provide a prospective international study on the indications, treatment modalities and outcomes of the management of renal masses. Each center participating in this project included all of the patients with the diagnosis of renal mass during a one-year period. Other examples of international multi-center collections were the CORONA and SATURN projects \[[@B5][@B6][@B7][@B8][@B9]\], which were not Web-based. Nevertheless, this type of multicenter collection is necessary to obtain better knowledge on RCC through a DB with a large cohort.

Data from 5,281 patients who underwent radical or partial nephrectomy were analyzed. Interestingly, incidentally detected renal mass accounted for 76.9% of the total patients. This rate was much higher than the rate of approximately 50% in a previous report \[[@B19]\]. Recently, the more common applications of imaging modalities for the evaluation of a variety of nonspecific symptoms has led to higher rates of incidental mass detection and an increased proportion of early stage tumors. More than half of the patients (54.3%) presented with clinical T1a stage tumors and metastatic tumors were identified only in 6.3% of patients. It is probable that this rate overestimated the real pattern of presentation because patients with advanced stage disease who were managed by hematooncologic department were not included in our DB system. This relatively higher proportion of low clinical stage contributed to excellent overall and cancer-specific survival rates. We will likely find more incidental tumors with lower stages with the increasing use of imaging studies in the future.

Nowadays, the use of minimally invasive surgery is a growing trend. An open approach was used in 50.7% and 52.2% of radical and partial nephrectomies, respectively. Minimally invasive approaches-such as laparoscopic and robotic surgeries-were used for the remaining cases. Interestingly, robotic approach was used in 3.1% and 23.8% of radical and partial nephrectomies, respectively. It is well known that the application of robotic surgery in partial nephrectomy can provide good surgical quality including a reduced ischemic time, due to its enhanced 3-dimensional vision and excellent degree of freedom \[[@B20][@B21]\]. These factors contributed to nearly a quarter of the patients undergoing partial nephrectomy being managed by a robotic approach. Although it represented a relatively lower (3.1%) proportion, robotic technology was also used in radical nephrectomy. Pure laparoscopic surgery is a challenging procedure, and some surgeons find laparoscopic radical nephrectomy difficult to perform. Robotic radical nephrectomy can bridge the gap between open and pure laparoscopic approaches for some urologists. As the number of people with private insurance has increased and the cost barrier is not an issue for these patients, the application of robotic technology will continuously increase in the future.

Another notable f inding was that proportion of clear cell type was higher (85.2%) in our DB compared to that in previous reports (60%-80%) \[[@B22][@B23]\]. Whether this phenomenon is Korean-specific is not known. The proportion of sarcomatoid differentiation has ranged from 2% to 5% in past reports; our DB revealed a proportion of 2.5%, which was equivalent to other reports \[[@B24][@B25]\].

There were some limitations in this DB. First, this type of retrospective collections could contain some errors in data entry. We crosschecked our data with alternate recorders to avoid some errors in data entry. In addition to this error, some patients\' data were lacking, causing incomplete data collections for some individual patients. Second, the length of FU length was rather short (mean, 32 months) but this weak point will be solved with long-term FU in the future. Third, this collection was based on the department of urology at each center. Some patients with advanced stage disease could visit the department of internal medicine and they could be managed without surgical intervention. This could lead to incomplete observation of the whole RCC spectrum in Korea. We are planning to expand this database to include patients of hematooncologic department. Then, the database will be able to represent the whole cohorts of Korean RCC.

In conclusion, the 1st Web-based DB system to collect RCC data was established in Korea. This DB will provide a solid basis for the characterization of KORCC.

CONCLUSIONS
===========

We report the 1st establishment of a Web-based DB system to collect RCC data in Korea. This DB will provide a solid basis for the characterization of KORCC.

We appreciate all members of the KORCC group for participating in this project. This research was supported by Seoul National University Bundang Hospital Research Fund (02-2012-027).

**CONFLICTS OF INTEREST:** The authors have nothing to disclose.

SUPPLEMENTARY MATERIAL
======================

Supplementary Table 1 can be found via <http://icurology.org/src/sm/icu-57-50-s001.pdf>.

###### Supplementary Table 1

Prognostic findings

![Kaplan-Meier curves of overall survival according to pathologic T stage (A), N stage (B), M stage (C), Fuhrman nuclear grade (D), and histologic type (E).](icu-57-50-g001){#F1}

![Kaplan-Meier curves of recurrence free survival according to pathologic T stage (A), N stage (B), M stage (C), Fuhrman nuclear grade (D), and histologic type (E).](icu-57-50-g002){#F2}

###### Basic characteristics (n=5,281)
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  Characteristic                      Value
  ----------------------------------- --------------
  Follow-up (mo), mean (IQR)          32 (12-61)
  Age (y)                             55.7±12.7
  Gender                              
   Male                               3,758 (71.2)
   Female                             1,523 (28.8)
  Height (cm)                         165.0±9.5
  Weight (kg)                         66.6±11.7
  Body mass index (kg/m^2^)           24.4±3.3
  Hypertension                        1,883 (38.5)
  Diabetes mellitus                   736 (14.9)
  Chronic kidney disease              915 (19.4)
  Smoking                             
   Nonsmoker                          2,570 (68.2)
   Ex-smoker                          458 (12.2)
   Current smoker                     738 (19.6)
  ECOG performance status             
   0                                  2,876 (65.4)
   1                                  883 (20.1)
   2                                  559 (12.7)
   3                                  74 (1.7)
   4                                  6 (0.1)
  ASA classification                  
   1                                  1,510 (41.9)
   2                                  1,884 (52.2)
   3                                  206 (5.7)
   4                                  8 (0.2)
  Symptom presentation at diagnosis   
   Incidentally detected              4,048 (76.9)
   Hematuria                          551 (10.4)
   Flank pain                         524 (8.2)
   Palpable mass                      52 (0.9)
   Etc                                184 (3.5)

Values are presented as mean±standard deviation or number (%) unless otherwise indicated.

IQR, interquartile range; ECOG, Eastern Cooperative Oncology Group; ASA, American Society of Anesthesiologists.

###### Preoperative findings
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  Variable                        Value
  ------------------------------- --------------
  Preop Hb (g/dL)                 13.7±1.9
  Preop serum Cr (mg/dL)          1.12±1.1
  Preop eGFR (mL/min/1.73 m^2^)   75.0±28.2
  Clinical T stage                
   T1a                            2,757 (54.3)
   T1b                            1,130 (22.3)
   T2a                            453 (8.9)
   T2b                            127 (2.5)
   T3a                            470 (9.3)
   T3b                            66 (1.3)
   T3c                            10 (0.2)
   T4                             65 (1.3)
  Clinical N stage                
   N0                             4,890 (96.3)
   N1                             188 (3.7)
  Clinical M stage                
   M0                             4,759 (93.7)
   M1                             319 (6.3)
  Tumor size (cm)                 4.8±4.2
  Tumor laterality                
   Left                           2,507 (49.4)
   Right                          2,541 (50.0)
   Bilateral                      30 (0.6)
  Tumor location                  
   Exophytic                      1,922 (48.1)
   Mesophytic                     696 (17.4)
   Endophytic                     846 (21.2)
   Hilar                          535 (13.4)

Values are presented as mean±standard deviation or number (%).

Preop, preoperative; Hb, hemoglobin; Cr, creatinine; eGFR, estimated glomerular filtration rate.

###### Type of surgery and ischemia
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  Variable                             Radical nephrectomy   Partial nephrectomy
  ------------------------------------ --------------------- ---------------------
  No. of patient                       3,311 (62.7)          1,970 (37.3)
  Type of surgery                                            
   Laparoscopic                        1,309 (39.5)          464 (23.6)
   HALS                                210 (6.3)             9 (0.5)
   Open                                1,680 (50.7)          1,029 (52.2)
   Robotic                             103 (3.1)             468 (23.8)
   LESS                                9 (0.3)               0 (0)
  Type of ischemia                                           
   Warm                                \-                    1,591 (83.0)
   Ice slush                           \-                    185 (9.6)
   Retrograde cold Saline irrigation   \-                    12 (0.6)
   Cold, otherwise                     \-                    30 (1.6)
   None                                \-                    100 (5.2)
  Ischemic time (min)                  \-                    25.2±11.3

Values are presented as number (%) or mean±standard deviation.

HALS, hand-assisted laparoscopic surgery; LESS, laparo-endoscopic single-site surgery.

###### Perioperative findings
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  Variable                       Value
  ------------------------------ -------------
  Operation time (min)           182.7±72.1
  EBL (mL)                       344.8±513.9
  Intraop transfusion            381 (7.2)
  Intraop complication           
   Colon                         12 (0.2)
   Duodenum                      4 (0.1)
   Liver                         10 (0.2)
   Pancreas                      11 (0.2)
   Spleen                        18 (0.3)
   Pleura                        113 (2.1)
   Major vessel                  41 (0.8)
   Ureter                        4 (0.1)
   Etc                           152 (2.9)
  Postop transfusion             189 (3.6)
  Postop Hb (g/dL)               12.3±2.0
  Postop complication            
   Cardiovascular                9 (0.2)
   Respiratory                   42 (0.8)
   Neurologic                    3 (0.1)
   Gastrointestinal              49 (0.9)
   Urologic                      72 (1.4)
   Etc                           369 (7.0)
  Postop complication grade^a^   
   Grade I                       189 (38.0)
   Grade II                      153 (30.8)
   Grade III                     3 (0.6)
   Grade IIIa                    114 (22.9)
   Grade IIIb                    26 (5.2)
   Grade IV                      6 (1.2)
   Grade IVa                     3 (0.6)
   Grade IVb                     0 (0)
   Grade V                       3 (0.6)

Values are presented as mean±standard deviation or number (%).

EBL, estimated blood loss; Intraop, intraoperative; Postop, postoperative; Hb, hemoglobin.

^a^:Proportion in complicated cases.

###### Pathologic characteristics
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  Variable                         Value
  -------------------------------- --------------
  Pathologic T stage               
   T1a                             2,915 (55.2)
   T1b                             1,052 (19.9)
   T2a                             387 (7.3)
   T2b                             117 (2.2)
   T3a                             619 (11.7)
   T3b                             105 (2)
   T3c                             13 (0.2)
   T4                              73 (1.4)
  Pathologic N stage               
   N0                              2,776 (52.7)
   N1                              165 (3.1)
   Nx                              2,331 (44.2)
  Pathologic M stage               
   M0                              4,925 (94.0)
   M1                              312 (6.0)
  Fuhrman nuclear grade            
   1                               238 (4.8)
   2                               2,586 (51.8)
   3                               1,867 (37.4)
   4                               306 (6.1)
  Histologic type                  
   Clear cell                      4,432 (85.2)
   Papillary                       81 (1.6)
   Papillary type 1                86 (1.7)
   Papillary type 2                127 (2.4)
   Chromophobe                     331 (6.4)
   Collecting duct                 19 (0.4)
   Unclassified                    55 (1.1)
   Multilocular cystic             27 (0.5)
   Mixed                           22 (0.4)
   Xp11.2 translocation            18 (0.3)
   Clear cell papillary            5 (0.1)
  Positive surgical margin (PNx)   79 (4.0)
  Tumor size (mm)                  44.4±32.0
  Sarcomatoid deferentiation       89 (2.5)
  Necrosis                         
   Microscopic                     191 (5.2)
   Macroscopic                     283 (7.8)
  Lymphovascular invasion          241 (5.2)
  Capsular invasion                816 (25.0)

Values are presented as number (%) or mean±standard deviation.

PNx, partial nephrectomy.

###### Overall, cancer specific and recurrence free survival rates at 2, 5, and 10 years after nephrectomy
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                                      2 Years   5 Years   10 Years
  ----------------------------------- --------- --------- ----------
  Overall survival rate (%)           94.1      88.0      76.3
  Cancer specific survival rate (%)   96.1      92.2      86.1
  Recurrence free survival rate (%)   92.6      88.0      78.4
